Medication
Wegovy HD 7.2 mg: the new injection option
The current Wegovy label includes a 7.2 mg weekly injection called Wegovy HD. The old site's blanket statement that Wegovy stops at 2.4 mg is no longer accurate.
Where the higher dose fits
Wegovy still begins with the standard weekly escalation from 0.25 mg. For the labeled adult weight-management population, a prescriber may increase to 7.2 mg after at least 4 weeks at 2.4 mg if additional weight reduction is clinically indicated and treatment is tolerated.
The label's indication and dosing limits matter. The HD option should not be applied automatically to adolescent treatment, MASH, or another indication because those uses have their own maintenance recommendations. Discuss whether a change is appropriate rather than assuming the highest dose is a treatment goal.
Sources: Wegovy prescribing information, including tablets and Wegovy HD
A distinct presentation needs training
Check the exact product and presentation supplied by the pharmacy. A 7.2 mg pen is not a reason to use multiple older pens, count clicks, or alter a device. Use the Instructions for Use that come with the prescribed product.
Presentation changes can affect administration and storage instructions. Have the pharmacist demonstrate unfamiliar equipment, and ask who handles a malfunction or uncertain dose. Do not repeat an injection simply because you are unsure whether it was delivered.
Sources: Wegovy prescribing information, including tablets and Wegovy HD
Older trials do not settle this comparison
SURMOUNT-5 compared tirzepatide with semaglutide at 1.7 or 2.4 mg weekly. It did not include 7.2 mg semaglutide. Its result cannot be used to claim that tirzepatide beats or loses to Wegovy HD.
The current Wegovy label describes evidence and adverse reactions for the higher dose, including more frequent altered skin sensations in the relevant study. Evaluate the higher dose's tolerability and benefit with a clinician rather than projecting an individual's response from an average.
Sources: SURMOUNT-5: tirzepatide compared with semaglutide for obesity · Wegovy prescribing information, including tablets and Wegovy HD
Cost, safety, and ongoing care
NovoCare pricing distinguishes Wegovy HD from standard injection and tablet offers. Check the prescribed presentation and long-term price, particularly after promotional fills. Insurance authorization for one formulation may not establish coverage for another.
The product retains the semaglutide contraindications and important warnings. Persistent severe gastrointestinal symptoms, dehydration, or severe abdominal pain need medical assessment. Re-escalation after missed consecutive injections should follow the current label with the prescriber.
Sources: NovoCare Wegovy patient support and savings · Wegovy prescribing information, including tablets and Wegovy HD
The decision is about additional benefit at a higher exposure
A higher labeled dose creates an option for selected adults needing further weight reduction after established 2.4 mg treatment. It does not create an obligation to increase whenever progress slows. Discuss the benefit already achieved, current tolerability, ongoing goals, and the reason additional reduction is clinically indicated. The label requires at least four weeks at 2.4 mg before the HD option is considered.
The higher-dose studies described in the label involve specific populations and durations, including different findings in populations with and without diabetes. Their averages should not be treated as the guaranteed additional loss for someone switching today. Also review adverse effects: the label reports altered skin sensations more frequently in the relevant higher-dose study. A symptom can matter to an individual even when the group-average efficacy result is favorable.
Sources: Wegovy prescribing information, including tablets and Wegovy HD
A useful comparison asks a narrower question
If the question is whether to continue standard Wegovy or discuss HD, evidence within the Wegovy label is more relevant than an old general ranking of injectable medicines. If the question is HD versus tirzepatide, SURMOUNT-5 cannot answer it because its semaglutide regimen was 1.7 or 2.4 mg. Treating that study as a direct HD comparison would change what was actually tested.
Similarly, the fact that 7.2 mg is three times 2.4 mg does not imply three times the weight reduction or a simple proportional change in adverse effects. Clinical responses must be measured, not calculated from dose ratios. Ask the clinician which outcome data apply to your diagnosis and whether continuing the current regimen, changing treatment, or obtaining additional support better fits the situation.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · SURMOUNT-5: tirzepatide compared with semaglutide for obesity
Prepare for the prescription and refill change
Confirm the product name, strength, presentation, and pharmacy price before the first HD fill. Use the supplied Instructions for Use rather than combining old devices to reproduce a new dose. The pharmacy should explain storage and handling for the presentation actually dispensed. If a dose is uncertain or the device malfunctions, obtain advice before repeating an injection.
Check whether insurance authorization and manufacturer offer terms apply to HD specifically. A standard Wegovy quote should not silently become the HD maintenance budget. Also establish what happens if tolerability changes or a refill is delayed. Consecutive missed injections need the current label's lower-dose re-escalation plan with the prescriber. Keep other clinicians informed of the new strength, particularly before a procedure or when managing diabetes medicines.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · NovoCare Wegovy patient support and savings
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.